Fig. 3: Cost-effectiveness analysis of different gBRCA testing policies in HER2-negative breast cancer patients.

a Cost-effectiveness ranking (China); b Cost-effectiveness ranking (USA); c Tornado diagram—net monetary benefits in the sensitivity analysis (China); d Tornado diagram—net monetary benefits in the sensitivity analysis (USA).